SCHEMBL2448744

SCHEMBL2448744

CCCn1cc(-c2cnc3ccc4ccc(N(C)S(=O)(=O)NC)cc4c(=O)c3c2)cn1

nearest known ligand 0.72

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.72
MST1R Q04912 1/20 0.55
KCNH2 Q12809 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2322770 0.89 MET (0.72) METMST1RKCNH2
SCHEMBL2447304 0.84 MET (1.00) METMST1RKCNH2
SCHEMBL2446196 0.83 MET (0.76) METMST1RKCNH2
SCHEMBL4296572 0.82 MET (0.76) METMST1R
SCHEMBL3952870 0.81 MET (0.69) METMST1RKCNH2
SCHEMBL2447158 0.81 MET (0.82) METMST1RKCNH2
SCHEMBL2447035 0.78 MET (0.81) METMST1R
SCHEMBL2452747 0.78 MET (0.69) METMST1RKCNH2
SCHEMBL4297592 0.77 MET (0.58) METMST1RKCNH2
SCHEMBL2447435 0.77 MET (1.00) METMST1RKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550478-B2 Tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 US claimed
US-8207186-B2 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET MERCK SHARP & DOHME CORP. (US) 2012-06-26 US disclosed
EP-1896421-B1 BENZOCYCLOHEPTAPYRIDINES AS INHIBITORS OF THE RECEPTOR TYROSINE KINASE MET MERCK SHARP & DOHME (US) 2011-09-14 EP disclosed
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MERCK SHARP & DOHME LLC 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197908-A1 Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met MET, RET, ERBB2 MET 1/4885MST1R 62/4885KCNH2 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.